[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ophthalmology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ophthalmology":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,92,128,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100584210","phase-4-optimizing-the-ocular-surface-with-systane-complete-pre--and-post-operatively-in-patients-with-dry-eye-planning-for-cataract-surgery-an-extension-study-of-optimizing-the-ocular-surface-with-systane-complete-in-patients-with-dry-eye-planning-for-cataract-surgery-100584210",false,"NCT06886373","Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery","Inclusion Criteria (Experimental group ): Cataract patients who participated in the \"Optimizing the Ocular Surface with Systane COMPLETE in Patients with Dry Eye Planning for Cataract Surgery\" trial (Research Ethics Committee Approval Number: 202311109MIPD) and did not withdraw from the trial midway.\n\nExclusion Criteria (Experimental group ): Patients unwilling to participate in this trial after surgery.\n\nInclusion Criteria(Control group):\n\n* Cataract patients aged between 20 and 85 years.\n* Patients with normal cognitive function who are able to complete the dry eye questionnaire (with - responses recorded by the research team) and are willing to undergo phacoemulsification and intraocular lens implantation under topical anesthesia.\n\nExclusion Criteria (Control group):\n\n* Unable to answer the questions in the dry eye survey.\n* Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts.\n* Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect.\n* Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin.\n* Using dry eye medication at screening stage.","ALL","20 Years","85 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Compare the corneal astigmatism data before and after the use of Systane COMPLETE to evaluate its impact on predicting changes in postoperative residual astigmatism, as well as the effects of using or not using Systane COMPLETE on preoperative and postoperative Ocular Surface Disease Index (OSDI) scores and Non-Invasive Tear Break-Up Time (NITBUT).",[26],"Ophthalmology",[28,29,30,31,32],"Dry eye","cataract surgery","astigmatism","nano-emulsion","artificial tears","RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":37},"2025-03-25",{"date":41,"type":20},"2027-12-31",{"name":43,"class":44},"National Taiwan University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":72,"locationsCount":45},"100583294","phase-4-an-extension-test-of-whether-to-use-oral-anti-anxiety-drugs-alprazolam-when-patients-choose-second-eye-cataract-surgery-after-unblinding-and-analyze-their-anxiety-satisfaction-and-pain-satisfaction-100583294","NCT06874452","An Extension Test of Whether to Use Oral Anti-anxiety Drugs (Alprazolam) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction","Pain, Anxiety and Anesthetic Satisfaction for Patient With Different State Anxiety Underwent Cataract Surgery With Topical Anesthesia. An Extension Test of Whether to Use Oral Anti-anxiety Drugs (Alprazolam) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction.","Inclusion Criteria:\n\n1. Age between 18 and 80 years old.\n2. Enrolled in \"Anxiety and surgery satisfaction for cataract patient with different state anxiety\" (Research Ethics Committee Case No.: 202302067MINB).\n3. Plan to undergo phacoemulsification and intraocular lens implantation surgery with topical anesthetic on the second eye at the Department of Ophthalmology.\n4. Subject who does not have side effect from XANAX.\n\nExclusion Criteria:\n\n1. Presence of any surgery contraindications.\n2. Presence of any medication contraindications.\n3. Inability to provide clear and complete answers to relevant questionnaires, or expression of no preoperative anxiety during the outpatient visit, or scores below 21 on the STAI-S or STAI-T assessment.\n4. Regular use of anti-anxiety medications, sleeping pills, or analgesics before the procedure.\n5. Pregnancy or breastfeeding during the preoperative period.\n6. Severe corneal diseases, overripe cataracts, small pupils, or lens dislocation leading to difficulties in conventional surgery.\n7. Patients under surface anesthesia who cannot fully cooperate with the surgical procedure.\n8. Pregnant or uncertain pregnancy status (women under 55 years old to be verbally asked by research team members).","18 Years","80 Years",{"count":56,"type":20},250,[23],"Phacoemulsification is one of the most used surgical methods for cataract surgery today, and the surgeries are under the anesthetic and sedative to make it comfortable and safe for patients. The most important issue is which method is the best for reducing the patient's anxiety, pain, and discomfort during surgery. Previous studies have analyzed the impact of intravenous injection of sedative on the quality of phacoemulsification surgery; however, the impact of oral anti-anxiety drugs (Alprazolam) on cataract surgery has not been intensively studied. Therefore, the purpose of this study is to investigate the impact of Alprazolam on satisfaction in cataract surgery. Oral sedation is more convenient and safer than intravenous sedation. Therefore, the investigators will further analyze whether patients using oral anti-anxiety drugs will have an improvement in the pain, anxiety, overall satisfaction, and side effects related to nausea and dizziness in the phacoemulsification surgery. This study will detailed record the patient's status in various aspects using questionnaire scales and scores. Through this research, the investigators will have the opportunity to comprehensively improve the surgical quality of cataract patients in a safe and convenient manner. The investigators plan to collect data from patients who participated in the study \"Anxiety and surgery satisfaction for cataract patient with different state anxiety\" (Research Ethics Committee Case No.: 202302067MINB) from October 2023 to August 2025, and plan to undergo phacoemulsification and intraocular lens implantation surgery in their second eye with local anesthetic at the Department of Ophthalmology, National Taiwan University Hospital. The sample size of 250 participants was determined based on the type of intervention, expected effect size, outcome variability, desired statistical significance, trial power, and experiences from similar studies. Vulnerable populations and those with any relevant contraindications will be excluded during the enrollment process. All medical records and surgical process data, including privacy-related information, will only be accessible to professional medical personnel for analysis. The focus of this study will be on intraoperative satisfaction, pain scores, relevant discomfort symptoms during the surgery, and postoperative anxiety assessment scales.",[26,60,61,62],"Cataract Surgery Anesthesia","Oral Anxiolytic","Satisfaction Survey",[64,65,66,67,68],"oral anti-anxiety drugs","oral anxiolytic","ophthalmology","cataract surgery anesthesia","satisfaction survey",{"date":36,"type":37},{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":45},"100574780","phase-4-optimizing-the-ocular-surface-with-systane-complete-in-patients-with-dry-eye-planning-for-cataract-surgery-100574780","NCT06763731","Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery","Inclusion Criteria:\n\nThe subjects aged 20-85 years, with normal cognitive function and capable of answering related questionnaires who require phacoemulsification and intraocular lens implantation under topical anaesthesia, are the eligible candidates.\n\nExclusion Criteria:\n\n1. Unable to answer the questions in the dry eye survey.\n2. Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts.\n3. Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect\n4. Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin.\n5. Using dry eye medication at screening stage",{"count":80,"type":20},150,[23],"Regular use of Systane COMPLETE in dry eye subjects before cataract surgery may optimize the ocular surface.",[26],[28,85],"Cataract surgery",{"date":87,"type":37},"2026-04-23",{"date":89,"type":37},"2024-05-02",{"date":41,"type":20},{"name":43,"class":44},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":15,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100623809","a-multimodal-ai-agent-for-ophthalmic-clinical-decision-support-100623809","NCT07401459","A Multimodal AI Agent for Ophthalmic Clinical Decision Support","Multicenter Randomized Controlled Trial of a Multimodal AI Agent for Ophthalmology Clinical Decision Support","Inclusion Criteria:\n\n1. Outpatient participants aged 6 to 75 years.\n2. Participants who undergo ophthalmic examinations for medical purposes during the study period.\n3. Participants who can produce clear ophthalmic images in both eyes.\n4. Agree to participate in this study with written informed consent:\n\n   1. Participants aged 18 years or older provide their own consent.\n   2. Participants aged 6-17 years require consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n1. Participants who are reluctant to participate in this study.\n2. Participants presenting with acute or emergency ocular conditions requiring immediate intervention.\n3. Participants with poor quality of ophthalmic images, including blurriness, artifacts, underexposure, or overexposure.\n4. Other unsuitable reasons determined by the evaluators.",true,"6 Years","75 Years",{"count":103,"type":20},300,[105],"NA","This study is a multicenter randomized controlled trial evaluating the effectiveness and safety of EyeAgent, a multimodal artificial intelligence (AI) agent designed to assist ophthalmologists in clinical decision-making. Participants will be recruited from ophthalmology clinics and hospitals in Hong Kong and mainland China. The AI agent acts as a digital co-pilot, analyzing patient images and clinical history to provide diagnostic and management recommendations. The trial aims to determine whether the use of the AI agent improves diagnostic accuracy, treatment decision-making performance, report generation, workflow efficiency, and user satisfaction compared to standard clinical practice.",[26,108,109,110,111],"Large Language Models","AI Agent","Eye Disease","Retinal Disease",[113,114,66,115,116,117],"medical AI agent","large language model","tool integration","clinical decision support","real world study","NOT_YET_RECRUITING","2026-02-19",{"date":121,"type":37},"2026-02-23",{"date":123,"type":20},"2026-03-01",{"date":125,"type":20},"2026-12-31",{"name":127,"class":44},"The Hong Kong Polytechnic University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":99,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100597840","identification-of-cellular-biomarkers-of-rare-eye-diseases-in-adults-100597840","NCT07063719","Identification of Cellular Biomarkers of Rare Eye Diseases in Adults","REVIBIO","Inclusion Criteria:\n\nPatient group:\n\n* Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study)\n* Willingness and ability to read and understand the informed consent.\n* Diagnosis (including genotype, if needed) of REDs.\n* Affiliation with a social security scheme or beneficiary of such a scheme.\n\nRED 1 - AAK Diagnosis criteria\n\n* Compatible slit lamp examination (iris\u002Fpupillary abnormalities, with or without corneal opacification, vascularization, cataract, glaucoma). with or without:\n* Foveal hypoplasia and optic disc malformations as detected through fundus examination or OCT tomography\n* Compatible anterior segment OCT or high-frequency ultrasound biomicroscopy (UBM)\n* Positive genetic testing\n\nRED 2 - NK Diagnosis criteria\n\n* Compatible history and slit lamp findings of one of the three stages of the Mackie classification (I - punctate keratopathy; II - persistent epithelial defect; III - stromal involvement)\n* Reduced\u002Fabsent corneal sensitivity\n* Exclusion of infectious or toxic etiologies with or without:\n* confocal microscopy findings\n\nRED 3 - LSCD Diagnosis criteria\n\n* Compatible history and slit lamp examination (e.g. corneal conjunctivalization with persistent epithelial defects, loss of limbal anatomy or irregular staining with fluorescein) with or without:\n* confocal microscopy findings\n\nRED 4 - OCP Diagnosis criteria\n\n* Compatible slit lamp examination\n* Exclusion of infectious or toxic etiologies with or without:\n* conjunctival \u002Foral biopsy with characteristic mucous pemphigoid findings\n\nRED 5 - OC GVHD Diagnosis criteria • Compatible history and slit lamp examination consistent with one of 4 grades of ocular GVHD (1 - conjunctival hyperemia, 2 - fibrovascular changes \\\u003C25% of palpebral conjunctiva, 3 - fibrovascular changes \\>25%, 4 - \\>75% or cicatricial entropion)\n\nRED 6 - EEC Diagnosis criteria\n\n* Compatible slit lamp examination\n* Compatible systemic findings with or without:\n* Positive genetic testing\n\nRED 7- CNV Diagnosis criteria\n\n* Compatible slit lamp examination of corneal stromal neovascularization (1-4 quadrants)\n* Exclusion of infectious or toxic etiologies with or without:\n* confocal microscopy findings\n\nControl group:\n\n* Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study).\n* Willingness and ability to read and understand the informed consent.\n* Non-diagnosis of REDs.\n* Affiliation with a social security scheme of beneficiary of such a scheme.\n\nExclusion Criteria:\n\nPatient group:\n\n* Pregnancy, breastfeeding (in case any stress was caused to the woman by the biological sampling).\n* Descemetocele\u002Fimpending corneal perforation.\n* Recent (less than 3 months) ocular surgery.\n* Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology.\n* Persons subject to a legal protection measure (under guardianship, curatorship or safeguard of justice)\n\nControl group:\n\n* Pregnancy, breastfeeding.\n* Active ocular infection.\n* Descemetocele\u002Fimpending corneal perforation.\n* Recent (less than 3 months) ocular surgery.\n* Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology.\n* Persons subject to a legal protection measure. (under guardianship, curatorship or safeguard of justice)",{"count":136,"type":20},110,[105],"The cornea is the outermost transparent 'window' of the eye allowing light to enter and serving as the first-line immune and mechanical barrier. It is a complex avascular tissue composed of cells, stem cells, nerves, and collagen layers organized in an exquisite manner to maintain its transparency and self-healing capacity. This delicately balanced interplay of corneal elements is disrupted in rare diseases of the cornea, resulting in non-healing wounds, corneal ulceration, inflammation, new vessel ingrowth (neovascularization), defective innervation, scarring, oedema and loss of transparency. For many Rare Eye Diseases (REDs), drug development has been relatively unsuccessful, delivering few to no new therapies. Current management is often prohibitively expensive, has low efficacy and leads to debilitating side effects. The RESTORE VISION project (https:\u002F\u002Frestorevision-project.eu\u002F) aims to improve eye health by using cutting-edge models for each rare disease to test novel and repurposed compounds (9 in total) and determine drug mechanisms of action, formulating compounds as safe eye drop suspensions, and performing several first-in-human trials of novel therapies. Thes drugs have solid preliminary data showing beneficial effects in restoring the cell physiology, immune, avascular, neural and signaling environment in the cornea.\n\nThe current clinical study is part of Work package 2 within the RESTORE VISION EU grant agreement (''Validation of human drug targets of repurposed drugs and novel therapies'') and aims to ascertain the expression levels of genes and proteins and investigate pathways of interest in human tissue and fluid samples of REDs, that are targeted by the proposed experimental\u002Frepurposed substances. Therapeutic target gene and\u002For protein expression will be verified in human blood, tears and conjunctival cells collected from 7 RED patient groups. The RESTORE VISION Consortium know multiple putative genes and proteins involved in the REDs and\u002For affected by the drugs to be tested in RED models. These will be analyzed in patient samples from the 7 REDs to see if they are 1) expressed at all; 2) differ in expression between patient and control group and 3) are correlated with clinical endpoints and\u002For symptoms of REDs.\n\nThe 7 REDs under investigation are briefly explained as follows:\n\n1. AAK: genetic progressive limbal stem cell degeneration leading to corneal neovascularization, inflammation, recurrent erosions, chronic pain and vision loss.\n2. OCP: autoimmune scarring of the conjunctiva leads to deficient wound healing, inflammation, scarring, blindness and pain.\n3. EEC Syndrome: Ectodermal Dysplasia causes pathological corneal scarring and blindness.\n4. NK: involves a corneal nerve deficit leading to reduction or loss of corneal sensitivity, impaired wound healing, corneal ulceration and loss of vision.\n5. LSCD: acquired or hereditary stem cell deficiency inducing epithelial breakdown, neovascularization, scarring and inflammation leading to decreased vision, tearing and pain.\n6. oGvHD: a severe side-effect of successful bone-marrow transplantation leads to painful and blinding ocular surface inflammation, neovascularization and delayed wound healing.\n7. CN: in high-risk transplantation, pathologic inflammation, corneal blood and lymphatic vessels are key risk factors for high-risk corneal graft failure, leading to graft rejection and blindness.",[140,26],"Rare Diseases",[142],"Rare occular disease","2025-12-04",{"date":145,"type":37},"2025-12-05",{"date":147,"type":20},"2026-01-20",{"date":149,"type":20},"2027-01-20",{"name":151,"class":152},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":172,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100606672","clinical-determinants-and-adverse-reactions-to-tropicamidephenylephrine-in-hospitalized-patients-100606672","NCT07178600","Clinical Determinants and Adverse Reactions to Tropicamide\u002FPhenylephrine in Hospitalized Patients.","Characterization and Association of Clinical Determinants With the Occurrence of Adverse Drug Reactions Following the Administration of Tropicamide\u002FPhenylephrine in Hospitalized Patients.","RAM-TF-IOCV","Inclusion Criteria:\n\n* Patients who have authorized participation in the study by signing informed consent.\n* Patients over 18 years of age.\n* Any sex.\n* Patients from the \"Instituto de Oftalmología Conde de Valenciana, IAP., sede Centro\" who have been scheduled for a surgical procedure.\n* Patients for whom the administration of two drops of tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL is indicated.\n* Patients that presents any type of disease\n\nExclusion Criteria:\n\n* Allergy to any component of the formulation.",{"count":163,"type":20},1000,"OBSERVATIONAL","To evaluate the association between clinical determinants and the occurrence of adverse drug reactions in hospitalized patients who received tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL.\n\nAn ambispective, interventional, longitudinal study will be conducted to actively identify adverse reactions to tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL, as well as the clinical determinants that may predispose patients to the occurrence of an adverse drug reaction (ADR). Data will be collected through the administration of a questionnaire and measurement of vital signs prior to the administration of tropicamide\u002Fphenylephrine 8 mg\u002F50 mg\u002FmL, and subsequently at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours after administration, with the aim of establishing an association between these variables.",[167,168,169,170,26,171],"Adverse Drug Effect","Phenylephrine","Hypertension","Cardiovascular Complication","Ocular Discomfort",[167,173,174,175,176,169,26,177],"Tropicamide\u002Fphenylefrine","Tropicamide","Phenylefrine","Cardiovascular complications","Ocular discomfort","2025-09-11",{"date":180,"type":37},"2025-09-17",{"date":182,"type":37},"2023-09-02",{"date":184,"type":20},"2026-09",{"name":186,"class":44},"Instituto de Oftalmología Fundación Conde de Valenciana"]